Mean change in HRQoL domains over 12 months related to baseline disease duration
| Disease duration (years) | Treatment | PF | RP | BP | GH | VT | SF | RE | MH | PCS | MCS | HAQ | Fatigue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Treatment groups are “Abatacept” = abatacept + MTX and “Placebo” = placebo + MTX. | |||||||||||||
| PF, physical functioning; RP, role physical; BP, bodily pain; GH, general health; VT, vitality; SF, social functioning; RE, role emotional; MH, mental health; PCS, physical component summary; MCS, mental component summary. | |||||||||||||
| *p<0.001; †p<0.01; ‡p<0.05; §p<0.1. | |||||||||||||
| ⩽2 | Abatacept | 8.85 (1.09) | 9.03 (1.24) | 9.72 (1.01) | 5.64 (0.85) | 7.78 (1.03) | 6.58 (1.16) | 7.77 (1.56) | 6.69 (1.11) | 8.62 (0.94) | 6.04 (1.15) | −0.74 (0.06) | −23.79 (2.87) |
| Placebo | 4.73 (1.69) | 7.42 (1.93) | 5.78 (1.58) | 5.78 (1.32) | 5.54 (1.60) | 6.62 (1.81) | 6.42 (2.42) | 3.37 (1.72) | 6.02 (1.46) | 4.85 (1.79) | −0.38 (0.10) | −16.37 (4.45) | |
| >2–5 | Abatacept | 8.40 (1.13) | 11.40 (1.30) | 14.28 (1.06) | 6.02 (0.89) | 7.78 (1.07) | 8.71 (1.21) | 11.35 (1.62) | 6.59 (1.16) | 10.13 (0.98) | 7.48 (1.20) | −0.76 (0.07) | −26.92 (2.99) |
| Placebo | 4.79 (1.63) | 4.45 (1.86) | 5.19 (1.52) | 2.52(1.28) | 3.87 (1.54) | 3.82 (1.74) | 4.79 (2.34) | 3.54 (1.66) | 4.25 (1.41) | 3.54 (1.73) | −0.38 (0.10) | −19.82 (4.30) | |
| >5–10 | Abatacept | 8.54 (1.06) | 9.73 (1.23) | 11.97 (1.00) | 6.63 (0.84) | 8.40 (1.02) | 9.24 (1.15) | 6.99 (1.54) | 6.53 (1.09) | 9.89 (0.93) | 6.23 (1.14) | −0.63 (0.06) | −25.34 (2.84) |
| Placebo | 5.96 (1.53) | 8.06 (1.75) | 7.07 (1.42) | 4.42 (1.20) | 6.01 (1.45) | 7.16 (1.64) | 8.53 (2.19) | 7.70 (1.56) | 5.49 (1.32) | 7.66 (1.62) | −0.38 (0.09) | −18.84 (4.03) | |
| >10 | Abatacept | 6.39 (0.94) | 7.89 (1.07) | 10.34 (0.88) | 7.39 (0.73) | 8.30 (0.89) | 8.49 (1.00) | 7.68 (1.34) | 5.94 (0.96) | 8.00 (0.81) | 6.89 (0.99) | −0.53 (0.06) | −26.66 (2.47) |
| Placebo | 3.79 (1.27) | 4.46 (1.45) | 6.36 (1.18) | 4.48 (0.99) | 4.32 (1.20) | 5.06 (1.35) | 5.92 (1.81) | 2.19 (1.29) | 4.78 (1.09) | 3.90 (1.34) | −0.39 (0.08) | −15.96 (3.34) | |
| F -statistic—disease duration | 1.24 | 1.45 | 1.11 | 1.00 | 0.41 | 0.71 | 0.21 | 2.02 | 0.56 | 0.59 | 0.97 | 0.28 | |
| F-statistic—treatment | 11.95* | 10.23† | 39.50* | 8.41† | 12.51* | 6.72† | 2.30 | 5.51‡ | 24.83* | 2.84§ | 25.76* | 10.38† | |
| F-statistic—interaction | 0.17 | 1.24 | 1.86 | 1.08 | 0.29 | 0.99 | 1.46 | 1.50 | 0.74 | 1.42 | 1.18 | 0.18 | |